AION Labs, a ‘first-of-its-kind’ innovation lab that will create and adopt AI technology to transform the process of drug discovery and development, has officially launched this month.
A new startup initiative in Israel aims to create and invest in startups that use artificial intelligence to address challenges in drug discovery and development. Called AION Labs, this innovation lab stems from an economic development effort from the Israeli government and will have contributions from AstraZeneca, Merck, Pfizer and Teva Pharmaceutical.
Pfizer, Merck, Teva, Amazon form consortium that runs AION Labs, an Israeli facility that will focus on harnessing artificial intelligence in drug development
/PRNewswire/ AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic.